<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262405</url>
  </required_header>
  <id_info>
    <org_study_id>1995-0304</org_study_id>
    <secondary_id>P50HL056402-06</secondary_id>
    <nct_id>NCT00262405</nct_id>
  </id_info>
  <brief_title>Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic
      pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and
      physiologic assessment at baseline. Subjects will be monitored off treatment for three months
      for changes in symptoms and physiology. Subjects will then be randomized to six months of
      treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is
      change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment.
      Secondary endpoints are progression free survival, change in dyspnea, change in quality of
      life, and change in physiology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LTB4 level in BAL</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRP score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>zileuton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zileuton</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azathioprine/prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azathioprine/prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
    <arm_group_label>zileuton</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine/prednisone</intervention_name>
    <arm_group_label>azathioprine/prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic pulmonary fibrosis

          -  Taking &lt; 15 mg prednisone for at least 30 days prior to screening

          -  Age 35-80, inclusive

          -  Able to understand a written informed consent and comply with the study protocol

        Exclusion Criteria:

          -  Significant environmental exposure

          -  Diagnosis of collagen vascular disease

          -  Evidence of active infection

          -  Clinically significant cardiac disease Myocardial infarction, coronary artery bypass
             or angioplasty within 6mo Unstable angina pectoris Congestive heart failure requiring
             hospitalization within 6 months Uncontrolled arrhythmia

          -  Poorly controlled or severe diabetes mellitus

          -  Pregnancy or lactation

          -  Women of childbearing potential not using a medically approved means of contraception
             (i.e. oral contraceptives, intrauterine devices, diaphragm, Norplant)

          -  Current enrollment in another experimental protocol

        Physiologic Criteria:

          -  FEV1/FVC &lt; 0.60

        Laboratory Criteria:

          -  Total bilirubin &gt; 1.5 X upper limit normal

          -  AST or ALT &gt; 3X upper limit normal

          -  Alkaline phosphatase &gt; 3X upper limit normal

          -  White blood cell count &lt; 2,500/mm3

          -  Hematocrit &lt; 30%

          -  Platelets &lt; 100,000/mm3

          -  Prothrombin time INR &gt; 1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galen B Toews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kevin R. Flaherty</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

